Edition:
United Kingdom

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

41.59USD
20 May 2019
Change (% chg)

$0.12 (+0.29%)
Prev Close
$41.47
Open
$41.49
Day's High
$41.71
Day's Low
$41.28
Volume
7,193,421
Avg. Vol
7,231,984
52-wk High
$46.46
52-wk Low
$35.32

About

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business... (more)

Overall

Beta: 0.99
Market Cap(Mil.): $214,682.30
Shares Outstanding(Mil.): 5,955.13
Dividend: 0.32
Yield (%): 3.55

Financials

  PFE.N Industry Sector
P/E (TTM): 26.26 29.30 32.55
EPS (TTM): 1.37 -- --
ROI: 6.00 14.23 13.82
ROE: 13.80 15.46 15.24

Pfizer's atopic dermatitis treatment meets goals in late-stage study

Pfizer Inc's new atopic dermatitis treatment met the main goals in a late-stage study that tested the drug in patients aged 12 and older with moderate to severe forms of the disease, the drugmaker said on Wednesday.

15 May 2019

UPDATE 1-Pfizer's atopic dermatitis treatment meets goals in late-stage study

May 15 Pfizer Inc's new atopic dermatitis treatment met the main goals in a late-stage study that tested the drug in patients aged 12 and older with moderate to severe forms of the disease, the drugmaker said on Wednesday.

15 May 2019

Pfizer's dermatitis treatment meets main goals of late-stage study

May 15 Pfizer Inc's dermatitis treatment met the main goals in a late-study, testing the drug in patients aged 12 and older with moderate to severe form of the disease, the drugmaker said on Wednesday.

15 May 2019

GSK-Pfizer deal gets approval from Australia's anti-trust watchdog

GlaxoSmithKline's deal to buy Pfizer's consumer healthcare business will not lesson competition in Australia, the country's anti-trust regulator said on Thursday as it approved the deal.

09 May 2019

GSK-Pfizer deal gets approval from Australia's anti-trust watchdog

GlaxoSmithKline's deal to buy Pfizer's consumer healthcare business will not lesson competition in Australia, the country's anti-trust regulator said on Thursday as it approved the deal.

09 May 2019

UPDATE 1-GSK-Pfizer deal gets approval from Australia's anti-trust watchdog

May 9 GlaxoSmithKline's deal to buy Pfizer's consumer healthcare business will not lesson competition in Australia, the country's anti-trust regulator said on Thursday as it approved the deal.

09 May 2019

Australia's anti-trust watchdog gives go-ahead for GSK-Pfizer consumer healthcare deal

May 9 Australia's competition regulator said on Thursday it will not oppose GlaxoSmithKline's deal to buy Pfizer's consumer healthcare business.

09 May 2019

Pfizer gets U.S. approval for $225,000 a year heart drug

NEW YORK The U.S. Food and Drug Administration on Monday approved Pfizer Inc's oral drug, tafamidis, to treat a rare and fatal heart disease called transthyretin amyloid cardiomyopathy, the U.S drugmaker said.

06 May 2019

UPDATE 2-Pfizer gets U.S. approval for $225,000 a year heart drug

NEW YORK, May 6 The U.S. Food and Drug Administration on Monday approved Pfizer Inc's oral drug, tafamidis, to treat a rare and fatal heart disease called transthyretin amyloid cardiomyopathy, the U.S drugmaker said.

06 May 2019

S&P 500 posts best four-month run in nearly nine years; Apple jumps after hours

NEW YORK The S&P 500 eked out another record high close on Tuesday and capped its best four-month stretch in nearly nine years after a recent rally that helped to restore investors' belief in the decade-long bull run. | Video

30 Apr 2019

Earnings vs. Estimates